Dr Cath Mummery (麻豆传媒视频网站 Queen Square Institute of Neurology), who led the UK team involved in Biogen鈥檚 trial of aducanumab, which has now been submitted for market approval, comments that the drug has shown a link between the rate of decline in the brain and amyloid proteins.
听
Close
